Bradley Canino
Stock Analyst at Stifel
(1.51)
# 3,520
Out of 5,140 analysts
82
Total ratings
32.88%
Success rate
-5.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $46 → $38 | $13.08 | +190.52% | 4 | Dec 2, 2025 | |
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $19.69 | +123.46% | 7 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.33 | +543.78% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $2.45 | -38.78% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $13.65 | +39.19% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $8.70 | +164.37% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $11.99 | +325.35% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $8.46 | +124.59% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $104.79 | -59.92% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $15.94 | +150.94% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $100.50 | +34.33% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $11.11 | +80.02% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.42 | +604.23% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.42 | +313.22% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.16 | +548.15% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $87.40 | -37.07% | 4 | Feb 23, 2024 |
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $46 → $38
Current: $13.08
Upside: +190.52%
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $19.69
Upside: +123.46%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.33
Upside: +543.78%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $2.45
Upside: -38.78%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $13.65
Upside: +39.19%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $8.70
Upside: +164.37%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $11.99
Upside: +325.35%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $8.46
Upside: +124.59%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $104.79
Upside: -59.92%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $15.94
Upside: +150.94%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $100.50
Upside: +34.33%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $11.11
Upside: +80.02%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.42
Upside: +604.23%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.42
Upside: +313.22%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.16
Upside: +548.15%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $87.40
Upside: -37.07%